PRESS RELEASE : HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.

DGAP-News: HAEMATO AG / Key word(s): Quarter Results/Quarterly / Interim Statement 
HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 
million. 
2021-05-31 / 08:37 
The issuer is solely responsible for the content of this announcement. 
=---------------------------------------------------------------------------------------------------------------------- 
______________________________________________________________________________ 
Corporate News of HAEMATO AG: 
HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 
million. 
Berlin, 31.05.2021 - HAEMATO AG (ISIN: DE000289VV1), has continued its growth course in the first months of 2021. Due 
to a strong core business, consolidated sales (IFRS) increased by 22 % to EUR 73.9 million in the first quarter of 
2021. The specialist in drugs for the treatment of chronic diseases and for individual therapies increased earnings 
disproportionately at all levels. The result from ordinary activities (EBITDA) rose by 196 % to EUR 2,823 thousand 
(previous year: EUR 954 thousand) and the operating result (EBIT) by 350% to EUR 2,428 thousand. Thus, after the first 
three months of the current year, EBIT already exceeds the figure for 2020 as a whole. One reason for the increase in 
earnings is the improvement in the gross margin, which has increased from 7.2 % (previous year) to 9.8 % in the first 
quarter of 2021. 
"HAEMATO has streamlined its product portfolio in recent years and consistently focused on high-margin areas with 
sustainable growth potential. This is paying off more and more," says HAEMATO CEO Patrick Brenske. "Today, our growth 
drivers are special pharmaceuticals against chronic diseases and products around aesthetic medicine. For medical 
cannabis, demand clearly exceeds our supply and we are currently looking for additional suppliers." 
At the end of March 2021, the subsidiary HAEMATO PHARM GmbH received special approval from the Federal Institute for 
Drugs and Medical Devices (BfArM) for a Covid 19 antigen rapid test for self-testing by laypersons. In April and May 
2021, a sales volume of almost EUR 25 million was already generated with the medical products from the "Diagnostics" 
segment, which will be positively reflected in the business figures for the second quarter of 2021. Medium-term demand 
for Covid 19 rapid tests depends largely on the further course of the pandemic, the vaccination rate and the national 
testing strategy in Germany. 
Due to the still ongoing Corona pandemic, HAEMATO AG will again make use of the option to invite shareholders to the 
company's Annual General Meeting scheduled for 13 July 2021 with a shortened notice period of 21 days. 
About HAEMATO: 
HAEMATO AG, founded in 1993, is a pharmaceutical company. The focus of its business activities is on the trading of 
high-priced special pharmaceuticals (with a therapeutic focus on cancer, HIV, and other chronic diseases) as well as 
the development and distribution of medical products and own brands, particularly in the field of "aesthetic medicine". 
HAEMATO AG is listed on the Basic Board (Open Market) of the Frankfurt Stock Exchange. Further information at: 
www.haemato.ag. 
Contact: 
HAEMATO AG, Investor Relations 
Telefon: [phone] 
[e-mail] 
=---------------------------------------------------------------------------------------------------------------------- 
2021-05-31 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG. 
The issuer is solely responsible for the content of this announcement. 
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. 
Archive at www.dgap.de 
=---------------------------------------------------------------------------------------------------------------------- 
Language:     English 
Company:      HAEMATO AG 
              Lilienthalstraße 5c 
              12529 Schönefeld 
              Germany 
Phone:        [phone] 
Fax:          [phone] 
E-mail:       [e-mail] 
Internet:     www.haemato.ag 
ISIN:         DE000A289VV1 
WKN:          A289VV 
Listed:       Regulated Unofficial Market in Berlin, Dusseldorf, Frankfurt (Basic Board), Hamburg, Stuttgart, Tradegate 
              Exchange 
EQS News ID:  1202340 
 
End of News   DGAP News Service 
=------------ 

1202340 2021-05-31

 
Image link: 
https://eqs-cockpit.com/cgi-bin/fncls.ssp?fn=show_t_gif&application_id=1202340&application_name=news

(END) Dow Jones Newswires

May 31, 2021 02:38 ET (06:38 GMT)